The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: Preliminary results of a 1-year follow-up study

Neurological Sciences

Volumn 32, Issue 1, 2011, Pages 83-88

  Mattioli, Flavia ^a   Stampatori, C ^a   Capra, R ^b  

^a Neuropsychology Unit   (Italy)

^b Multiple Sclerosis Centre   (Italy)

Author keywords

Cognitive function; Multiple sclerosis; Natalizumab; Relapsing remitting

Indexed keywords

METHYLPREDNISOLONE; NATALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED ORAL WORD ASSOCIATION TEST; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PACED AUDITORY SERIAL ADDITION TEST; RELAPSE; VERBAL MEMORY; WISCONSIN CARD SORTING TEST;

ADULT; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 79551600627     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-010-0412-4     Document Type: Article

References (29)

1. IFNB Multiple Sclerosis Study Group 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 43 655 661
2. KP Johnson BR Brooks JA Cohen CC Ford J Goldstein RP Lisak, et al. 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1268 1276 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D 7617181
3. TA Yednock C Cannon LC Fritz F Sanchez-Madrid L Steinman N Karin 1992 Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 63 66 1:CAS:528:DyaK38Xhslaisbw%3D 10.1038/356063a0 1538783
4. RA Rudick A Sandrock 2004 Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS Expert Rev Neurother 4 571 580 1:CAS:528:DC%2BD2cXmtlSms7Y%3D 10.1586/14737175.4.4.571 15853576
5. CH Polman PW O'Connor E Havrdova M Hutchinson L Kappos DH Miller, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 1:CAS:528:DC%2BD28XitVertL4%3D 10.1056/NEJMoa044397 16510744
6. E Havrdova S Galetta M Hutchinson D Stefoski D Bates CH Polman, et al. 2009 Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol 8 254 260 10.1016/S1474-4422(09)70021-3 19201654
7. RA Rudick D Miller S Hass M Hutchinson PA Calabresi C Confavreux, et al. 2007 Health-related quality of life in multiple sclerosis: effects of natalizumab Ann Neurol 62 335 346 1:CAS:528:DC%2BD2sXhsVSjurrK 10.1002/ana.21163 17696126
8. RA Rudick WH Stuart PA Calabresi C Confavreux SL Galetta EW Radue, et al. 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 1:CAS:528:DC%2BD28XitVertLw%3D 10.1056/NEJMoa044396 16510745
9. MS Deloire E Salort M Bonnet Y Arimone M Boudineau H Amieva, et al. 2005 Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis J Neurol Neurosurg Psychiatry 76 519 526 1:STN:280:DC%2BD2M7ktlelug%3D%3D 10.1136/jnnp.2004.045872 15774439
10. F Patti MP Amato M Trojano S Bastianello MR Tola B Goretti, et al. 2009 Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study Mult Scler 15 779 788 1:STN:280:DC%2BD1MrotFegsg%3D%3D 10.1177/1352458509105544 19542262
11. DH Miller D Soon KT Fernando DG MacManus GJ Barker TA Yousry, et al. 2007 MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS Neurology 68 1390 1401 1:CAS:528:DC%2BD2sXktlSms7g%3D 10.1212/01.wnl.0000260064. 77700.fd 17452584
12. ND Chiaravalloti J DeLuca 2008 Cognitive impairment in multiple sclerosis Lancet Neurol 7 1139 1151 10.1016/S1474-4422(08)70259-X 19007738
13. F Patti 2009 Cognitive impairment in multiple sclerosis Mult Scler 15 2 8 1:STN:280:DC%2BD1M%2FhslWgsA%3D%3D 10.1177/1352458508096684 18805842
14. CM Poser DW Paty L Scheinberg WI McDonald FA Davis GC Ebers, et al. 1983 New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227 231 1:STN:280:DyaL3s3gt1OgtQ%3D%3D 10.1002/ana.410130302 6847134
15. JF Kurtzke 1983 Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1444 1452 1:STN:280:DyaL2c%2FktValsQ%3D%3D 6685237
16. DM Gronwall 1977 Paced auditory serial-addition task: a measure of recovery from concussion Percept Mot Skills 44 367 373 1:STN:280: DyaE2s7ptlejtA%3D%3D 866038
17. EA Berg 1948 A simple objective technique for measuring flexibility in thinking J Gen Psychol 39 15 22 1:STN:280:DyaH1c%2FjtlaisQ%3D%3D 10.1080/00221309.1948.9918159 18889466
18. G Novelli C Papagno E Capitani N Laiacona G Vallar SF Cappa 1986 Tre test clinici di ricerca e produzione lessicale.Taratura su soggetti normali Arch Psicol Neurol Psichiatr 47 477 506
19. H Spinnler G Tognoni 1987 Standardizzazione e taratura italiana di test neuropsicologici Ital J Neurol Sci 8 Suppl 1 120
20. Rao SM, Cognitive Function Study Group N (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society, New York
21. Meyers J, Meyers K (1995) Rey complex figure and recognition trial: professional manual. Psychological Assessment Resources, Odessa
22. C Christodoulou WS MacAllister NA McLinskey LB Krupp 2008 Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 22 87 97 1:CAS:528:DC%2BD1cXivFKkt7g%3D 10.2165/00023210-200822020-00001 18193921
23. JS Fischer RL Priore LD Jacobs DL Cookfair RA Rudick RM Herndon, et al. 2000 Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group Ann Neurol 48 885 892 1:CAS:528:DC%2BD3MXhtlKqsg%3D%3D 10.1002/1531-8249(200012)48:6<885::AID- ANA9>3.0.CO;2-1 11117545
24. F Patti MP Amato MR Tola M Trojano P Ferrazza S Bastianello 2008 Effects of subcutaneous interferon beta on disease parameters and cognition in patients with early relapsing-remitting multiple sclerosis: longitudinal clinical and cognitive result from the COGIMUS (Cognitive Impairment in Multiple Sclerosis) study Neurology 70 A87
25. NH Pliskin DP Hamer DS Goldstein VL Towle AT Reder A Noronha, et al. 1996 Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b Neurology 47 1463 1468 1:CAS:528:DyaK2sXjsFylsQ%3D%3D 8960728
26. Y Barak A Achiron 2002 Effect of interferon-beta-1b on cognitive functions in multiple sclerosis Eur Neurol 47 11 14 1:CAS:528: DC%2BD38XmtFGjtQ%3D%3D 10.1159/000047940 11803186
27. S Flechter J Vardi Y Finkelstein L Pollak 2007 Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study Isr Med Assoc J 9 457 459 1:CAS:528:DC%2BD2sXot1Sgur8%3D 17642394
28. A Weinstein SR Schwid RB Schiffer MP McDermott DW Giang AD Goodman 1999 Neuropsychologic status in multiple sclerosis after treatment with glatiramer Arch Neurol 56 319 324 1:STN:280:DyaK1M3gsFSqtQ%3D%3D 10.1001/archneur.56.3.319 10190822
29. SR Schwid AD Goodman A Weinstein MP McDermott KP Johnson 2007 Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial J Neurol Sci 255 57 63 10.1016/j.jns.2007.01.070 17331542